John Renger

John Renger

Company: Cerevel Therapeutics

Job title: Ph.D, Chief Scientific Officer

Seminars:

Development of CVL-231 for the Treatment of Psychosis 10:00 am

• CVL-231 was rationally designed as a positive allosteric modulator (PAM) that selectively targets the muscarinic acetylcholine 4 (M4) receptor subtype • Harnessing the anti-psychotic benefit believed to be associated with M4 while minimizing the side effects typically associated with panmuscarinic agonists • Phase 1b data readout • Plans to further evaluate the potential of…Read more

day: Day One

Live Q&A 10:50 am

Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.